FDA
-
-
-
-
-
-
-
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
-
-
-
-
-
-
-
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
-
-
-
-
-
-
-
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
-
-
-
-
-
-
-
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer
-
-
-
-
-
-
-
AEON Biopharma (AEON) Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on AEON Biopharma, Inc (AEON)
-
-
-
-
-
-
-
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

